Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Fennec Pharmaceuticals

NASDAQ FENC
$9.00 -0.18 -1.96%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 26.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
167.95M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
164.63M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.27
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
27.58M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
42.41 %

Upcoming events Fennec Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Fennec Pharmaceuticals

Stock analysis Fennec Pharmaceuticals

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-11.63 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
-31.33 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-19.29 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.39 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-579.61 -50.00

Price change Fennec Pharmaceuticals per year

3.99$ 9.24$
Min Max

Summary analysis Fennec Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Fennec Pharmaceuticals

Revenue and net income Fennec Pharmaceuticals

All parameters

About company Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Address:
68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
Company name: Fennec Pharmaceuticals
Issuer ticker: FENC
ISIN: CA31447P1009
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2001-06-05
Sector: Healthcare
Industry: Biotechnology
Site: https://www.fennecpharma.com